Biosimilar and Biologics Market Outlook from 2024 to 2034
The global biosimilar & biologics market size is expected to expand from US$ 520.9 billion in 2024 to a staggering US$ 1,060.7 billion by 2034. It will likely exhibit robust growth, with overall sales of biosimilars & biologics rising at 7.6% CAGR.
Global Biosimilar and Biologics Market Insights
Attributes
Key Insights
Base Market Value (2023)
US$ 480.1 billion
Estimated Biosimilar and Biologics Market Value (2024)
Customize your report by selecting specific countries or regions and save 30%!
Biosimilar and Biologics Market Overview
Biosimilars and biologics are revolutionizing the healthcare landscape by offering innovative treatments, enhancing patient outcomes, and increasing accessibility. As a result, their demand is growing significantly across the world.
Growing popularity of biosimilar biologics or biosimilar biologic drugs due to their higher effectiveness and affordability is expected to foster market growth.
Biologics have revolutionized the treatment of various diseases by offering targeted therapies that specifically address disease mechanisms. Unlike traditional small molecule drugs, which often have off-target effects, biologics and biosimilars are designed to precisely target pathways, minimizing adverse reactions.
Advances in biotechnology and manufacturing technologies have enabled more efficient and cost-effective production of biologics and biosimilars. They are changing the biologics manufacturing dynamics. Novel expression systems, cell culture techniques, and purification methods have improved yield, purity, and consistency of biological products, reducing production costs and increasing scalability. This is expected to foster growth of the biologics & biosimilar market.
Pharma manufacturers specializing in biosimilar and biologic production employ strategies to stay ahead of the competition. These include research and development activities, introduction of artificial intelligence for innovative therapies, strategic collaborations for novel drug development, and geographic expansion to tap into diverse markets.
Emphasis on regulatory approvals and cost-effectiveness contributes to product adoption and enhances market growth.
Key Factors Propelling Biosimilar and Biologics Market Growth Include
Rising prevalence of chronic diseases like cancer and diabetes
Growing need for effective and affordable treatments
Surging popularity of biologics like insulin, vaccines, and gene therapy
Increasing prices of drugs, along with rising healthcare costs
Find your sweet spots for generating winning opportunities in this market.
Opportunities in the Biosimilar and Biologics Industry
Increasing acceptance of biosimilars due to their cost-effectiveness
Expiration of patents on biologics
Supportive regulatory environment
Introduction of favorable reimbursement policies in developing and developed nations
Latest Trends in the Biosimilar and Biologics Market
Advancements in biomanufacturing technology
Shifting preference toward value-based care
Growing demand for personalized and targeted therapies
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need and save 40%!
Historical Performance Vs. Future Biosimilar and Biologic Sales Outlook
Global biosimilar and biologic sales grew at a CAGR of 5.8% from 2019 to 2023. Total market valuation at the end of 2023 reached around US$ 480.1 billion at the end of 2023. Over the forecast period, the global market for biosimilars and biologics is set to expand at 7.6% CAGR.
The emergence of orphan drugs as the new standard of care in rare diseases marks a significant advancement in biosimilars and biologics. Orphan drugs target rare diseases, which often lack effective treatment options due to their low prevalence and complexity. By providing innovative therapies for conditions with limited or no existing treatments, orphan drugs fill critical gaps in patient care and improve outcomes for individuals affected by these diseases.
Many orphan drugs represent first-in-class therapies, introducing novel mechanisms of action. Despite targeting niche patient populations, orphan drugs have demonstrated remarkable commercial success. Sales exceeding US$ 1 billion within a few years of market entry highlight the significant demand for these therapies and the willingness of healthcare systems to invest in treatments for rare diseases.
Examples such as Hemlibra (emicizumab) for hemophilia A with factor VIII inhibitors, lanadelumab for hereditary angioedema, and patisiran for hereditary transthyretin amyloidosis illustrate the transformative impact of orphan drugs. These therapies have shown promising results in clinical trials and are expected to become the new standard of care for their respective indications. Hence, the rise of orphan drugs as the new standard of care represents a paradigm shift in healthcare, offering hope and improved outcomes for individuals living with rare diseases.
Insights into Factors Propelling Biosimilars and Biologics Market Growth
Advancements in Biosimilar and Biologic Production
The pharmaceutical industry has seen significant advancements in developing and manufacturing biosimilars and biologics, presenting numerous opportunities for innovation, growth, and improved patient access to essential therapies. Advances in biotechnology and manufacturing technologies have enabled more efficient and cost-effective production of biologics and biosimilars.
Manufacturers of the original biologics can leverage bio-better development strategies to reinforce their market position and defend against competition, including biosimilars, by offering upgraded versions of their products with enhanced sensitivity. Novel expression systems, cell culture techniques, and purification methods have improved biological products' yield, purity, and consistency, driving down production costs and increasing scalability.
Sophisticated analytical techniques, manufacturing processes, and the introduction of artificial intelligence have facilitated in-depth characterization and comparability assessment of biosimilars with their reference products. These analytical advancements ensure biosimilars' quality, safety, and efficacy, supporting regulatory approval and market acceptance.
Regulatory agencies globally have established clear pathways and guidelines for developing and approving biosimilars. These established pathways reduce barriers to entry for biosimilar developers, encouraging competition and market growth.
The biosimilar market is increasingly globalizing, with manufacturers from both developed and emerging countries participating in biosimilar and biologic development and commercialization. Nations like India, China, and South Korea are emerging as key players in the biosimilar & biologic landscape, offering cost-competitive manufacturing capabilities.
Overview of Factors Limiting Growth of the Biosimilar and Biologics Market
Multiple factors limit the expansion of the global biosimilar and biologics market globally. These include regulatory complexities, high development costs, and supply chain issues.
Biosimilars require extensive clinical trials and data to demonstrate their safety and similarity to original biologics. This leads to lengthy and expensive development processes, thereby limiting market expansion to some extent.
Biosimilars and biologics necessitate specific handling protocols, including refrigeration and stringent processing, to prevent contamination by microorganisms and other impurities. Given that these products are typically administered via injection or intravenous infusion, maintaining sterility is very important to avoid a lethal impact on the patient’s life.
Due to their distinctive characteristics and the complexities involved in their production and distribution, biologics are often categorized as specialty drugs. Adherence to stringent good manufacturing practices (GMP), guidelines, and regulations is essential to ensure that manufacturing facilities are designed, operated, and maintained to minimize contamination risks and uphold aseptic conditions.
Another factor that may affect the uptake of biosimilars is that a biosimilar generally cannot be automatically substituted for the reference product (i.e., brand-name biologic) at the pharmacy level unless it is determined to be interchangeable with the reference product. An interchangeable product should have the same effect as the original product for each patient.
Unlike generic drugs, where substitution at the pharmacy level is typically automatic, biosimilars cannot be automatically substituted for the reference product unless they have been determined to be interchangeable by regulatory authorities. This is negatively impacting market growth.
An interchangeable biosimilar should meet specific criteria set by regulatory agencies, such as the CDSCO in India and the FDA in the United States. These criteria typically include demonstrating that the biosimilar produces the same clinical result as the reference product in any given patient and that switching between the biosimilar and the reference product does not pose greater risk than using the reference product alone.
Comparative View of Adjacent Biosimilar and Biologics Market
The global market for biosimilars and biologics is set to be impacted by the peer or tangential markets in the healthcare industry. These include the global biologics industry and the interchangeable biosimilar market.
Among these markets, the global biologics market is poised to grow rapidly during the assessment period. This is due to rising demand for biologics to treat several chronic diseases.
Global Biosimilar and Biologics Market Analysis:
Attribute
Global Biosimilar & Biologics Market Analysis
CAGR (2024 to 2034)
7.6%
Growth Factor
Rising cases of cancer and other chronic diseases and growing need for affordable treatments are key factors expected to drive growth of the biosimilar & biologics market.
Biosimilar & Biologics Market Trends
Growing interest in personalized treatments is a key growth shaping trend.
Global Biologics Market Outlook:
Attribute
Global Biologics Market Analysis
CAGR (2024 to 2034)
8.5%
Growth Factor
Increasing prevalence of chronic disease is providing impetus for the growth of biologics market.
Biologics Market Trends
A notable market-shaping trend is the ongoing innovation in biological medicines.
Interchangeable Biosimilar Demand Outlook:
Attribute
Global Interchangeable Biosimilar Market Analysis
CAGR (2024 to 2034)
6.0%
Growth Factor
Rising need for cost-effective treatments for diseases like cancer, diabetes, etc., is expected to drive the interchangeable biosimilar industry growth.
Interchangeable Biosimilar Market Trends
Expanding reach and therapeutic areas and rising popularity of insulin biosimilars will improve the interchangeable biosimilar market size through 2034.
Country-wise Insights
The table below shows the estimated growth rates of the top five countries. The United States, China, and Spain are set to record high CAGRs of 5.9%, 8.8%, and 7.4%, respectively, through 2034.
Market Growth Outlook by Key Countries
Countries
Value CAGR
United States
5.9%
China
8.8%
Japan
4.0%
Germany
4.6%
Spain
7.4%
United States to Retain its Monopoly in the Biosimilar and Biologics Industry
The United States is expected to dominate the global biosimilar & biologics market during the forecast period. It will likely register steady growth, with overall demand for biosimilars and biologics rising at a CAGR of 5.9% through 2034.
Rising incidence of chronic illnesses like cancer, autoimmune disorders, and diabetes is a key factor propelling demand for biosimilars & biologics in the nations. This is because these diseases often require treatment with biologics.
High adoption of biosimilars in the United States will likely boost the market during the assessment period.
The competitive landscape in the United States healthcare sector fosters innovation and high standards of care. The nation is home to several leading medical research institutions, technology companies, and healthcare providers. The collaborative environment and access to cutting-edge research can foster innovation in pharmaceutical market, including biosimilars and biologics.
A well-established regulatory framework for pharmaceuticals overseen by the Food and Drug Administration (FDA) is expected to benefit the market. Companies that successfully navigate and comply with these regulations may gain a competitive edge, as FDA approval is often seen as a benchmark for quality and safety.
Introduction of government health initiatives and programs, such as the Affordable Care Act, will continue to encourage adoption of biosimilars and biologics, thereby boosting sales growth.
Top biosimilar & biologic manufacturers in the United States are constantly investing in research to develop novel treatment solutions. This will likely enhance the United States’ biosimilar and biologics market share through 2034.
Growing Popularity of Biosimilars Boosting Sales Growth in China
China is emerging as a highly lucrative market for biosimilars & biologics, and the trend will likely persist during the forecast period. As per the latest analysis, sales of biosimilars and biologics in China are anticipated to grow at 8.8% CAGR through 2034.
High disease burden and growing popularity of affordable medications like biosimilars are key factors driving sales growth in China.
Growing demand for precision medicine approaches, including personalized biologic therapies tailored to individual patients' genetic makeup and disease characteristics, will likely facilitate market expansion in the country.
Advancements in genomics, biomarker identification, targeted therapy development, and investment in the biopharmaceutical sector are other factors influencing the China market.
Category-wise Insights
The table section offers deeper insights into leading segments in the global industry. The information will likely help companies maximize profits and stay ahead of the curve.
Based on drug class, the monoclonal antibody is expected to dominate the market, holding a value share of 31.0% in 2024.
By source, the bacterial cells segment is set to progress at 6.7% CAGR, holding a prominent market share of 44.0% in 2024.
In terms of application, the oncology segment will likely expand at 6.2% CAGR, accounting for a revenue share of 25.9% in 2024.
By distribution channel, pharmacies segment is estimated to hold a market share of 37.5% in 2024.
Based on manufacturing type, contract manufacturing segment is anticipated to have a value share of 56.7% in 2024.
Rising Adoption of Monoclonal Antibodies in Targeted Therapy Driving Demand
Market Growth Outlook by Drug Class
Drug
Value CAGR
Monoclonal Antibody
5.7%
Vaccines
9.4%
Recombinant Insulin
7.8%
Growth factors
6.7%
Immune Modulators
8.5%
Fusion Protein
6.9%
Erythoprotein
11.1%
Therapeutic Enzymes
10.1%
Interferons
12.9%
Colony Stimulation Factors
11.9%
Oligonucleotides
13.9%
Others Drug
5.8%
As per the latest analysis, the monoclonal antibody segment is expected to dominate the global biosimilar & biologic industry during the forecast period. It will likely rise at a CAGR of 5.7%, generating revenue worth US$ 161.1 billion in 2024.
Growing usage of monoclonal antibodies in targeted therapies is a key factor driving the target segment forward.
Monoclonal antibodies are designed to target specific molecules, such as proteins and cells, with high precision. This specificity reduces the possibility of off-target effects, making them suitable for treating a wide range of diseases.
Monoclonal antibodies can be engineered to target various diseases, including cancer cells, autoimmune disorders, and infectious agents. This versatility allows for the development and manufacturing of biotherapeutics for diverse medical conditions.
Rising prevalence of chronic diseases like cancer and diabetes is expected to drive demand for effective treatments, including monoclonal antibodies.
Specific advantages of monoclonal antibodies, including their minimal side effects, makes them attractive to both patients and healthcare professionals.
Development of high-quality and cost-effective biosimilars for mAbs due to advancements in biosimilar technology will further boost the target segment.
Bacterial Cells to be the Top Sources for Biosimilar and Biologic Production
Market Growth Outlook by Source
Source
Value CAGR
Bacterial Cells
6.7%
Yeast Cells
8.2%
Plant Cells
9.9%
Animal Cells
7.4%
Other Sources
8.8%
Bacterial cells are widely used for producing biosimilars and biologics. This is due to their multiple advantages, including faster and cheaper production, scalability, and lower immunogenicity.
The bacterial cells segment is estimated to account for a dominant market share of 44.0% in 2024. Further, it will likely witness a CAGR of 6.7% during the forecast period, totaling a valuation of US$ 229.2 billion in 2024.
Bacterial cells, such as Escherichia coli (E. coli) and Bacillus subtilis, are relatively easy and inexpensive to culture and manipulate in laboratories, making them cost-effective sources for large-scale biologics production.
Bacterial cells with short doubling times are allowing for rapid growth and high yields of recombinant proteins within a relatively short period. This is advantageous for meeting the high demand for biosimilars and biologics in the pharmaceutical market.
Due to the versatility of bacterial cells, they can be engineered to express a wide range of proteins, including enzymes, antibodies, and hormones. This makes them ideal for producing a large variety of biologics and biosimilars.
Oncology to be a Highly Remunerative Application for Biosimilars and Biologics
Market Growth Outlook by Application
Application
Value CAGR
Oncology
6.2%
Autoimmune Disease
6.9%
Infectious Diseases
8.9%
Rare Disease
9.7%
Cardiovascular Disorders
10.6%
Hematological Disorders
7.8%
Others Application
8.3%
Based on application, the oncology segment is anticipated to generate significant revenue for the biosimilar & biologics market. It will likely grow at a CAGR of 6.2% during the assessment period, totaling US$ 134.8 billion in 2024. This can be attributed to factors like:
Rising cancer cases globally
Increasing demand for effective and affordable treatments
Growing awareness and acceptance of biosimilars in cancer treatments
Increased life expectancy and improved diagnostics lead to more cancer diagnoses, driving the need for effective treatments. Advancements in personalized medicine require diverse treatment options customized to individual patients' mutations and tumor profiles. Biologics and biosimilars offer this diversity.
The prevalence of cancer is increasing globally due to factors such as aging population, lifestyle changes, and environmental factors. As cancer rates rise, there is a greater need for effective treatments, including biologics.
Biologics, including monoclonal antibodies and targeted therapies, have become standard treatments for lung cancer. These pharmaceuticals possess improved efficacy and reduced toxicity compared to traditional chemotherapy.
Contract Manufacturing Segment Leading the Global Industry
Market Growth Outlook by Manufacturing Type
Manufacturing Type
Value CAGR
Contract Manufacturing
7.4%
In-house Manufacturing
7.9%
The contract manufacturing industry is expected to lead the biosimilar and biologic industry during the assessment period, holding a share of 56.7% in 2024. Over the forecast period, the target segment will likely exhibit a CAGR of 7.4%.
Contract manufacturing organizations (CMOs) have specialized expertise and state-of-the-art facilities dedicated to specific manufacturing processes for biologics production. As a result, pharmaceutical giants often opt for contract manufacturing.
CMOs offer economies of scale, flexible capacity, and optimized production processes, resulting in lower manufacturing costs for pharmaceutical companies.
Contract manufacturing allows pharmaceutical companies to quickly produce biosimilar and biologics without investing in their own manufacturing capabilities.
Contract manufacturing can be more cost-effective than building and maintaining in-house manufacturing facilities. As a result, this segment is dominating the target industry.
Rising trend of pharmaceutical outsourcing is expected to further boost the contract manufacturing segment through 2034.
Hospital Pharmacies Witnessing High Sales of Biosimilars and Biologics
Market Growth Outlook by Distribution Channel
Distribution Channel
Value CAGR
Hospital Pharmacies
6.8%
Retail Pharmacies
7.7%
Specialty Pharmacies
8.2%
Mail Order Pharmacies
8.8%
In terms of distribution channel, the hospital pharmacies segment is poised to exhibit a CAGR of 6.8% during the forecast period. It will likely account for a revenue share of 37.5% in 2024.
Hospital pharmacies serve as a centralized distribution channel for medication procurement, storage, dispensing, and management within healthcare institutions.
Pharmaceutical companies manufacturing biosimilars and biologics can streamline their distribution processes by supplying medications directly to hospital pharmacies, reducing logistical complexities and ensuring efficient inventory management.
Competitive Landscape
Key manufacturers of biosimilars and biologics are rigorously investing in research and development to develop novel solutions for different applications, including cancer treatments. They are employing strategies like collaborations, mergers, acquisitions, partnerships, facility expansions, and distribution agreements to expand their footprint and stay ahead of the competition.
Recent Developments in the Biosimilar and Biologics Market
In January 2024, Gilead Sciences and Arcus Biosciences announced an amended collaboration agreement along with a separate equity investment. Gilead invested US$ 320 billion in Arcus common stock at US$ 21 per share. This strategic move aims to accelerate the growth of both companies through enhanced collaboration and increased financial support.
In October 2021, Boehringer Ingelheim inaugurated a biopharmaceutical production facility in Vienna, Austria. With this addition, the company strengthened its position in the European region.
Key Players in the Biosimilar and Biologics Market
Pfizer Inc.
Hoffmann-La Roche AG
AbbVie Inc.
Novartis AG
Merck & Co., Inc.
Bristol Myers Squibb Co.
GSK plc
AstraZeneca
Eli Lilly & Co.
Bayer AG.
Gilead Sciences
Amgen Inc.
Boehringer Ingelheim International GmbH
Novo Nordisk A/S
Viatris Inc.
Johnson & Johnson (Janssen Pharmaceuticals, Inc.)
Sanofi Winthrop Industries S.A
Serum Institute of India
Biocon Limited
Intas Pharmaceuticals Limited
Key Coverage in the Global Biosimilar and Biologics Market Research Report
Adjacent Study on Global Complex Biologics Market, Biosimilar Antibodies Market, Generic Biologics Market, and Biosimilar Products Market
Detailed Analysis of Global Biologics Manufacturing Market
A Separate Chapter Dedicated to Biosimilar Drugs Market Vs Biologic Drugs Market Analysis
Factors Propelling the Global Biosimilars Market
Growth Prospects for the Biosimilars & Biologics Market in India
Recent Advances in the Biopharmaceuticals Market
Demand Outlook for Biosimilars in India and other Developing Nations
The Potential and Challenges of Bringing Biosimilars to Market
Promising Opportunities of Biosimilar in the Middle East and Africa Market
Anticipated Impact of Biosimilars on Pharmaceutical Companies
Biosimilar and Biologics Market Segmentation
By Drug Class:
Monoclonal Antibody
Vaccines
Recombinant Insulin
Growth Factors
Immune Modulators
Fusion Protein
Erythoprotein
Therapeutic Enzymes
Interferons
Colony Stimulation Factors
Oligonucleotides
Others Drug
By Source:
Bacterial Cells
Yeast Cells
Plant Cells
Animal Cells
Other Sources
By Application:
Oncology
Autoimmune Disease
Infectious Diseases
Rare Disease
Cardiovascular Disorders
Hematological Disorders
Other Application
By Manufacturing Type:
Contract Manufacturing
In-house Manufacturing
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Specialty Pharmacies
Mail Order Pharmacies
By Region:
North America
Latin America
East Asia
South Asia & Pacific
Western Europe
Eastern Europe
Middle East & Africa
Frequently Asked Questions
How big is the biosimilar & biologics market?
The global biosimilar & biologics market value is set to reach US$ 520.9 billion in 2024.
What is the future of biosimilars and biologics?
By 2034, the biologics and biosimilar market size is expected to reach US$ 1,060.7 billion.
What was the historical CAGR for the global market?
The global market for biosimilars & biologics increased at 5.8% CAGR from 2019 to 2023.
What is the demand outlook for biosimilars and biologics?
Demand for biosimilar & biologics is projected to grow at 7.6% CAGR.
Which drug class segment dominates the market?
With 31.0% share in 2023, the monoclonal antibody segment dominated the global market.
What is the United States market outlook?
The United States biosimilar & biologics market is estimated to grow at 5.9% CAGR.
What is the sales forecast for China market?
Biosimilar & biologic sales in China are estimated to surge at 8.8% CAGR through 2034.
What are biologics and biosimilars?
Biologics are medications derived from living organisms, while biosimilars are medications similar to existing biologics.
How big is the biologics market?
The biologics market was valued at around US$ 335.4 billion in 2021.
Table of Content
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Supply-Side Trends
1.4. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
2.3. Inclusions and Exclusions
3. Key Market Trends
3.1. Key Trends Impacting the Market
3.2. Product Development/Innovation Trends
4. Value-Added Insights
4.1. Product Adoption Analysis
4.2. Disease Epidemiology
4.3. Pipeline Analysis
4.4. Regulatory Guidelines
4.4.1. Legal Requirements and Frameworks in the United States
4.4.2. Legal Requirements and Frameworks in Europe
4.4.3. Legal Requirements and Frameworks in Japan
4.4.4. Legal Requirements and Frameworks in China
4.4.5. Legal Requirements and Frameworks in India
4.5. Unmet Needs Analysis
4.6. PESTEL Analysis
4.7. Porters Analysis
4.8. Value Chain Analysis
4.9. Biosimilar Development
5. Market Background
5.1. Macro-Economic Factors
5.1.1. Global Healthcare Expenditure
5.1.2. R & D funding by Region
5.1.3. R & D funding by Country
5.2. Forecast Factors - Relevance and Impact
5.2.1. Regulatory Environment
5.2.2. Patent Expirations
5.2.3. Healthcare Expenditure
5.2.4. Biosimilar Pipeline
5.2.5. Clinical Evidence and Physician Acceptance
5.2.6. Market Access and Distribution Channels
5.2.7. Therapeutic Area Dynamics
5.2.8. Biosimilar Competition
5.3. Market Dynamics
5.3.1. Drivers
5.3.2. Restraints
5.3.3. Opportunity Analysis
6. Global Market Demand (in Value or Size in US$ billion) Analysis 2019 to 2023 and Forecast, 2024 to 2034
6.1. Historical Market Value (US$ billion) Analysis, 2019 to 2023
6.2. Revenue Opportunity Analysis
6.3. Current and Future Market Value (US$ billion) Projections, 2024 to 2034
6.3.1. Y-o-Y Growth Trend Analysis
6.3.2. Absolute $ Opportunity Analysis
7. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Drug Class
7.1. Introduction / Key Findings
7.2. Historical Market Size (US$ billion) Analysis By Drug Class, 2019 to 2023
7.3. Current and Future Market Size (US$ billion) Analysis and Forecast By Drug Class, 2024 to 2034
7.3.1. Monoclonal Antibody
7.3.2. Vaccines
7.3.3. Recombinant Insulin
7.3.4. Growth Factors
7.3.5. Immune Modulators
7.3.6. Fusion Protein
7.3.7. Erythoprotein
7.3.8. Therapeutic Enzymes
7.3.9. Interferons
7.3.10. Colony Stimulation Factors
7.3.11. Oligonucleotides
7.3.12. Others Drug
7.4. Market Attractiveness Analysis By Drug Class
8. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Source
8.1. Introduction / Key Findings
8.2. Historical Market Size (US$ billion) Analysis By Source, 2019 to 2023
8.3. Current and Future Market Size (US$ billion) Analysis and Forecast By Source, 2024 to 2034
8.3.1. Bacterial Cells
8.3.2. Yeast Cells
8.3.3. Plant Cells
8.3.4. Animal Cells
8.3.5. Other Sources
8.4. Market Attractiveness Analysis By Source
9. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Application
9.1. Introduction / Key Findings
9.2. Historical Market Size (US$ billion) Analysis By Application, 2019 to 2023
9.3. Current and Future Market Size (US$ billion) Analysis and Forecast By Application, 2024 to 2034
9.3.1. Oncology
9.3.2. Autoimmune Disease
9.3.3. Infectious Diseases
9.3.4. Rare Disease
9.3.5. Cardiovascular Disorders
9.3.6. Hematological Disorders
9.3.7. Other Application
9.4. Market Attractiveness Analysis By Application
10. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Manufacturing Type
10.1. Introduction / Key Findings
10.2. Historical Market Size (US$ billion) By Manufacturing Type, 2019 to 2023
10.3. Current and Future Market Size (US$ billion) Analysis and Forecast by Manufacturing Type, 2024 to 2034
10.3.1. Contract Manufacturing
10.3.2. In-house Manufacturing
10.4. Market Attractiveness Analysis by Manufacturing Type
11. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Distribution Channel
11.1. Introduction / Key Findings
11.2. Historical Market Size (US$ billion) By Distribution Channel, 2019 to 2023
11.3. Current and Future Market Size (US$ billion) Analysis and Forecast by Distribution Channel, 2024 to 2034
11.3.1. Hospital Pharmacies
11.3.2. Retail Pharmacies
11.3.3. Specialty Pharmacies
11.3.4. Mail Order Pharmacies
11.4. Market Attractiveness Analysis by Manufacturing Type
12. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Region
12.1. Introduction / Key Findings
12.2. Historical Market Size (US$ billion) Trend Analysis by Region, 2019 to 2023
12.3. Current and Future Market Size (US$ billion) Analysis and Forecast by Region, 2024 to 2034
12.3.1. North America
12.3.2. Latin America
12.3.3. East Asia
12.3.4. South Asia and Pacific
12.3.5. Western Europe
12.3.6. Eastern Europe
12.3.7. Middle East and Africa
12.4. Market Attractiveness Analysis by Region
13. North America Market Analysis 2019 to 2023 and Forecast 2024 to 2034
13.1. Introduction
13.2. Historical Market Size (US$ billion) Trend Analysis by Market Taxonomy, 2019 to 2023
13.3. Current and Future Market Size (US$ billion) Analysis and Forecast by Market Taxonomy, 2024 to 2034
13.3.1. By Country
13.3.1.1. United States
13.3.1.2. Canada
13.3.1.3. Mexico
13.3.2. By Drug Class
13.3.3. By Source
13.3.4. By Application
13.3.5. By Manufacturing Type
13.3.6. By Distribution Channel
13.4. Market Attractiveness Analysis
13.4.1. By Country
13.4.2. By Drug Class
13.4.3. By Source
13.4.4. By Application
13.4.5. By Manufacturing Type
13.4.6. By Distribution Channel
13.5. Market Trends
13.6. Drivers and Restraints Impact Analysis
13.7. Country-Wise Analysis
13.7.1. United States Market Analysis
13.7.1.1. Introduction
13.7.1.2. Market Analysis and Forecast by Market Taxonomy
13.7.1.2.1. By Drug Class
13.7.1.2.2. By Source
13.7.1.2.3. By Application
13.7.1.2.4. By Manufacturing Type
13.7.1.2.5. By Distribution Channel
13.7.2. Canada Market Analysis
13.7.2.1. Introduction
13.7.2.2. Market Analysis and Forecast by Market Taxonomy
13.7.2.2.1. By Drug Class
13.7.2.2.2. By Source
13.7.2.2.3. By Application
13.7.2.2.4. By Manufacturing Type
13.7.2.2.5. By Distribution Channel
13.7.3. Mexico Market Analysis
13.7.3.1. Introduction
13.7.3.2. Market Analysis and Forecast by Market Taxonomy
13.7.3.2.1. By Drug Class
13.7.3.2.2. By Source
13.7.3.2.3. By Application
13.7.3.2.4. By Manufacturing Type
13.7.3.2.5. By Distribution Channel
14. Latin America Market Analysis 2019 to 2023 and Forecast 2024 to 2034
14.1. Introduction
14.2. Historical Market Size (US$ billion) Trend Analysis by Market Taxonomy, 2019 to 2023
14.3. Current and Future Market Size (US$ billion) Analysis and Forecast by Market Taxonomy, 2024 to 2034
14.3.1. By Country
14.3.1.1. Brazil
14.3.1.2. Chile
14.3.1.3. Rest of Latin America
14.3.2. By Drug Class
14.3.3. By Source
14.3.4. By Application
14.3.5. By Manufacturing Type
14.3.6. By Distribution Channel
14.4. Market Attractiveness Analysis
14.4.1. By Country
14.4.2. By Drug Class
14.4.3. By Source
14.4.4. By Application
14.4.5. By Manufacturing Type
14.4.6. By Distribution Channel
14.5. Market Trends
14.6. Drivers and Restraints Impact Analysis
14.7. Key Market Players Intensity Mapping
14.8. Country-Wise Analysis
14.8.1. Brazil Market Analysis
14.8.1.1. Introduction
14.8.1.2. Market Analysis and Forecast by Market Taxonomy
14.8.1.2.1. By Drug Class
14.8.1.2.2. By Source
14.8.1.2.3. By Application
14.8.1.2.4. By Manufacturing Type
14.8.1.2.5. By Distribution Channel
14.8.2. Chile Market Analysis
14.8.2.1. Introduction
14.8.2.2. Market Analysis and Forecast by Market Taxonomy
14.8.2.2.1. By Drug Class
14.8.2.2.2. By Source
14.8.2.2.3. By Application
14.8.2.2.4. By Manufacturing Type
14.8.2.2.5. By Distribution Channel
15. East Asia Market Analysis 2019 to 2023 and Forecast 2024 to 2034
15.1. Introduction
15.2. Historical Market Size (US$ billion) Trend Analysis by Market Taxonomy, 2019 to 2023
15.3. Current and Future Market Size (US$ billion) Analysis and Forecast by Market Taxonomy, 2024 to 2034
15.3.1. By Country
15.3.1.1. China
15.3.1.2. Japan
15.3.1.3. South Korea
15.3.2. By Drug Class
15.3.3. By Source
15.3.4. By Application
15.3.5. By Manufacturing Type
15.3.6. By Distribution Channel
15.4. Market Attractiveness Analysis
15.4.1. By Country
15.4.2. By Drug Class
15.4.3. By Source
15.4.4. By Application
15.4.5. By Manufacturing Type
15.4.6. By Distribution Channel
15.5. Market Trends
15.6. Drivers and Restraints Impact Analysis
15.7. Country-Wise Analysis
15.7.1. China Market Analysis
15.7.1.1. Introduction
15.7.1.2. Market Analysis and Forecast by Market Taxonomy
15.7.1.2.1. By Drug Class
15.7.1.2.2. By Source
15.7.1.2.3. By Application
15.7.1.2.4. By Manufacturing Type
15.7.1.2.5. By Distribution Channel
15.7.2. Japan Market Analysis
15.7.2.1. Introduction
15.7.2.2. Market Analysis and Forecast by Market Taxonomy
15.7.2.2.1. By Drug Class
15.7.2.2.2. By Source
15.7.2.2.3. By Application
15.7.2.2.4. By Manufacturing Type
15.7.2.2.5. By Distribution Channel
15.7.3. South Korea Market Analysis
15.7.3.1. Introduction
15.7.3.2. Market Analysis and Forecast by Market Taxonomy
15.7.3.2.1. By Drug Class
15.7.3.2.2. By Source
15.7.3.2.3. By Application
15.7.3.2.4. By Manufacturing Type
15.7.3.2.5. By Distribution Channel
16. South Asia and Pacific Market Analysis 2019 to 2023 and Forecast 2024 to 2034
16.1. Introduction
16.2. Historical Market Size (US$ billion) Trend Analysis by Market Taxonomy, 2019 to 2023
16.3. Current and Future Market Size (US$ billion) Analysis and Forecast by Market Taxonomy, 2024 to 2034
16.3.1. By Country
16.3.1.1. India
16.3.1.2. ASEAN Countries
16.3.1.3. Australia and New Zealand
16.3.1.4. Rest of South Asia and Pacific
16.3.2. By Drug Class
16.3.3. By Source
16.3.4. By Application
16.3.5. By Manufacturing Type
16.3.6. By Distribution Channel
16.4. Market Attractiveness Analysis
16.4.1. By Country
16.4.2. By Drug Class
16.4.3. By Source
16.4.4. By Application
16.4.5. By Manufacturing Type
16.4.6. By Distribution Channel
16.5. Market Trends
16.6. Drivers and Restraints Impact Analysis
16.7. Country-Wise Analysis
16.7.1. India Market Analysis
16.7.1.1. Introduction
16.7.1.2. Market Analysis and Forecast by Market Taxonomy
16.7.1.2.1. By Drug Class
16.7.1.2.2. By Source
16.7.1.2.3. By Application
16.7.1.2.4. By Manufacturing Type
16.7.1.2.5. By Distribution Channel
16.7.2. ASEAN Countries Market Analysis
16.7.2.1. Introduction
16.7.2.2. Market Analysis and Forecast by Market Taxonomy
16.7.2.2.1. By Drug Class
16.7.2.2.2. By Source
16.7.2.2.3. By Application
16.7.2.2.4. By Manufacturing Type
16.7.2.2.5. By Distribution Channel
16.7.3. Australia and New Zealand Market Analysis
16.7.3.1. Introduction
16.7.3.2. Market Analysis and Forecast by Market Taxonomy
16.7.3.2.1. By Drug Class
16.7.3.2.2. By Source
16.7.3.2.3. By Application
16.7.3.2.4. By Manufacturing Type
16.7.3.2.5. By Distribution Channel
17. Western Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034
17.1. Introduction
17.2. Historical Market Size (US$ billion) Trend Analysis by Market Taxonomy, 2019 to 2023
17.3. Current and Future Market Size (US$ billion) Analysis and Forecast by Market Taxonomy, 2024 to 2034
17.3.1. By Country
17.3.1.1. Germany
17.3.1.2. Italy
17.3.1.3. France
17.3.1.4. United Kingdom
17.3.1.5. Spain
17.3.1.6. BENELUX
17.3.1.7. Rest of Western Europe
17.3.2. By Drug Class
17.3.3. By Source
17.3.4. By Application
17.3.5. By Manufacturing Type
17.3.6. By Distribution Channel
17.4. Market Attractiveness Analysis
17.4.1. By Country
17.4.2. By Drug Class
17.4.3. By Source
17.4.4. By Application
17.4.5. By Manufacturing Type
17.4.6. By Distribution Channel
17.5. Market Trends
17.6. Drivers and Restraints Impact Analysis
17.7. Country-Wise Analysis
17.7.1. Germany Market Analysis
17.7.1.1. Introduction
17.7.1.2. Market Analysis and Forecast by Market Taxonomy
17.7.1.2.1. By Drug Class
17.7.1.2.2. By Source
17.7.1.2.3. By Application
17.7.1.2.4. By Manufacturing Type
17.7.1.2.5. By Distribution Channel
17.7.2. Italy Market Analysis
17.7.2.1. Introduction
17.7.2.2. Market Analysis and Forecast by Market Taxonomy
17.7.2.2.1. By Drug Class
17.7.2.2.2. By Source
17.7.2.2.3. By Application
17.7.2.2.4. By Manufacturing Type
17.7.2.2.5. By Distribution Channel
17.7.3. France Market Analysis
17.7.3.1. Introduction
17.7.3.2. Market Analysis and Forecast by Market Taxonomy
17.7.3.2.1. By Drug Class
17.7.3.2.2. By Source
17.7.3.2.3. By Application
17.7.3.2.4. By Manufacturing Type
17.7.3.2.5. By Distribution Channel
17.7.4. United Kingdom Republic Market Analysis
17.7.4.1. Introduction
17.7.4.2. Market Analysis and Forecast by Market Taxonomy
17.7.4.2.1. By Drug Class
17.7.4.2.2. By Source
17.7.4.2.3. By Application
17.7.4.2.4. By Manufacturing Type
17.7.4.2.5. By Distribution Channel
17.7.5. Spain Market Analysis
17.7.5.1. Introduction
17.7.5.2. Market Analysis and Forecast by Market Taxonomy
17.7.5.2.1. By Drug Class
17.7.5.2.2. By Source
17.7.5.2.3. By Application
17.7.5.2.4. By Manufacturing Type
17.7.5.2.5. By Distribution Channel
17.7.6. BENELUX Market Analysis
17.7.6.1. Introduction
17.7.6.2. Market Analysis and Forecast by Market Taxonomy
17.7.6.2.1. By Drug Class
17.7.6.2.2. By Source
17.7.6.2.3. By Application
17.7.6.2.4. By Manufacturing Type
17.7.6.2.5. By Distribution Channel
18. Eastern Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034
18.1. Introduction
18.2. Historical Market Size (US$ billion) Trend Analysis by Market Taxonomy, 2019 to 2023
18.3. Current and Future Market Size (US$ billion) Analysis and Forecast by Market Taxonomy, 2024 to 2034
18.3.1. By Country
18.3.1.1. Russia
18.3.1.2. Hungary
18.3.1.3. Poland
18.3.1.4. Rest of Eastern Europe
18.3.2. By Drug Class
18.3.3. By Source
18.3.4. By Application
18.3.5. By Manufacturing Type
18.3.6. By Distribution Channel
18.4. Market Attractiveness Analysis
18.4.1. By Country
18.4.2. By Drug Class
18.4.3. By Source
18.4.4. By Application
18.4.5. By Manufacturing Type
18.4.6. By Distribution Channel
18.5. Market Trends
18.6. Drivers and Restraints Impact Analysis
18.7. Country-Wise Analysis
18.7.1. Poland Market Analysis
18.7.1.1. Introduction
18.7.1.2. Market Analysis and Forecast by Market Taxonomy
18.7.1.2.1. By Drug Class
18.7.1.2.2. By Source
18.7.1.2.3. By Application
18.7.1.2.4. By Manufacturing Type
18.7.1.2.5. By Distribution Channel
18.7.2. Hungary Market Analysis
18.7.2.1. Introduction
18.7.2.2. Market Analysis and Forecast by Market Taxonomy
18.7.2.2.1. By Drug Class
18.7.2.2.2. By Source
18.7.2.2.3. By Application
18.7.2.2.4. By Manufacturing Type
18.7.2.2.5. By Distribution Channel
18.7.3. Russia Market Analysis
18.7.3.1. Introduction
18.7.3.2. Market Analysis and Forecast by Market Taxonomy
18.7.3.2.1. By Drug Class
18.7.3.2.2. By Source
18.7.3.2.3. By Application
18.7.3.2.4. By Manufacturing Type
18.7.3.2.5. By Distribution Channel
19. Middle East and Africa Market Analysis 2019 to 2023 and Forecast 2024 to 2034
19.1. Introduction
19.2. Historical Market Size (US$ billion) Trend Analysis by Market Taxonomy, 2019 to 2023
19.3. Current and Future Market Size (US$ billion) Analysis and Forecast by Market Taxonomy, 2024 to 2034
19.3.1. By Country
19.3.1.1. Saudi Arabia
19.3.1.2. Türkiye
19.3.1.3. South Africa
19.3.1.4. Other African Union
19.3.1.5. Rest of Middle East & Africa
19.3.2. By Drug Class
19.3.3. By Source
19.3.4. By Application
19.3.5. By Manufacturing Type
19.3.6. By Distribution Channel
19.4. Market Attractiveness Analysis
19.4.1. By Country
19.4.2. By Drug Class
19.4.3. By Source
19.4.4. By Application
19.4.5. By Manufacturing Type
19.4.6. By Distribution Channel
19.5. Market Trends
19.6. Drivers and Restraints Impact Analysis
19.7. Country-Wise Analysis
19.7.1. Saudi Arabia Market Analysis
19.7.1.1. Introduction
19.7.1.2. Market Analysis and Forecast by Market Taxonomy
19.7.1.2.1. By Drug Class
19.7.1.2.2. By Source
19.7.1.2.3. By Application
19.7.1.2.4. By Manufacturing Type
19.7.1.2.5. By Distribution Channel
19.7.2. Türkiye Market Analysis
19.7.2.1. Introduction
19.7.2.2. Market Analysis and Forecast by Market Taxonomy
19.7.2.2.1. By Drug Class
19.7.2.2.2. By Source
19.7.2.2.3. By Application
19.7.2.2.4. By Manufacturing Type
19.7.2.2.5. By Distribution Channel
19.7.3. South Africa Market Analysis
19.7.3.1. Introduction
19.7.3.2. Market Analysis and Forecast by Market Taxonomy
19.7.3.2.1. By Drug Class
19.7.3.2.2. By Source
19.7.3.2.3. By Application
19.7.3.2.4. By Manufacturing Type
19.7.3.2.5. By Distribution Channel
19.7.4. Other African Union Market Analysis
19.7.4.1. Introduction
19.7.4.2. Market Analysis and Forecast by Market Taxonomy
19.7.4.2.1. By Drug Class
19.7.4.2.2. By Source
19.7.4.2.3. By Application
19.7.4.2.4. By Manufacturing Type
19.7.4.2.5. By Distribution Channel
20. Market Structure Analysis
20.1. Company Share Analysis
20.2. Market Presence Analysis
21. Competition Analysis
21.1. Branding and Promotional Strategies
21.2. Competition Deep Dive
21.2.1. Pfizer Inc.
21.2.1.1. Overview
21.2.1.2. Service Portfolio
21.2.1.3. Key Financials
21.2.1.4. SWOT Analysis
21.2.1.5. Key Developments
21.2.1.6. Strategy Overview
21.2.1.6.1. Marketing Strategy
21.2.1.6.2. Product Strategy
21.2.1.6.3. Channel Strategy
21.2.2. F.Hoffmann-La Roche AG
21.2.3. AbbVie Inc.
21.2.4. Novartis AG
21.2.5. Merck and Co., Inc.
21.2.6. Bristol Myers Squibb Co.
21.2.7. GSK plc
21.2.8. AstraZeneca
21.2.9. Eli Lilly and Co.
21.2.10. Bayer AG.
21.2.11. Gilead Sciences
21.2.12. Amgen Inc.
21.2.13. Boehringer Ingelheim International GmbH
21.2.14. Novo Nordisk A/S
21.2.15. Viatris Inc.
21.2.16. Johnson and Johnson (Janssen Pharmaceuticals, Inc.)
21.2.17. Sanofi Winthrop Industries S.A (1/4)
21.2.18. Serum Institute of India
21.2.19. Biocon Limited
21.2.20. Intas Pharmaceuticals Limited
22. Assumptions and Acronyms Used23. Research Methodology
